Sign in Subscribe
Biotechnology industries

Xechem International Receives Orphan Drug Designation, Stock Focus List Highlights

Strategic Insights

— 2 min read

Xechem International Inc.'s (OTCBB: XKEM) announcement that it has received Orphan Drug designation from the FDA for its compound 5-HMF to treat sickle cell disease positions the company uniquely in the pipeline for treating this condition. The SUBWAY.com has added Xechem International, Human Genome Sciences, Inc., Rambus Inc., and Cognos to their Stock Focus List, highlighting their performance in recent sessions.

Key Takeaways:

  • Xechem International Inc. (OTCBB: XKEM) received Orphan Drug designation from the FDA for its compound 5-HMF to treat sickle cell disease, providing the company with various incentives, including seven years of marketing exclusivity.
  • The SUBWAY.com's Stock Focus List includes Xechem International, Human Genome Sciences, Inc. (NASDAQ: HGSI), Rambus Inc. (NASDAQ: RMBS), and Cognos (NASDAQ: COGN), which have all shown a 1% increase in recent sessions.
  • Chairman and CEO of Xechem, Dr. Ramesh Pandey, expressed the company's satisfaction with the FDA's decision, highlighting the dual-drug pipeline for treating sickle cell disease.
  • The company's inclusion on the Stock Focus List is not indicative of a long-term view and is based on recent performance.
  • CRG's compensation from the companies mentioned, including $30,000 for XKEM and $120,000 in past compensation for XKEM, may have influenced their investment recommendations.
  • CRG's affiliates, officers, directors, and employees may have bought or may buy shares of the profiled companies and may profit from a rise in value.

Statistics:

  • Xechem International Inc. (OTCBB: XKEM) received Orphan Drug designation for its 5-HMF compound, providing the company with market exclusivity for a period of seven years.
  • The company's Chairman and CEO, Dr. Ramesh Pandey, stated that the FDA's decision "puts Xechem into a unique position."
  • Xechem's Orphan Drug designation entitles the company to various incentives, including the waiver of Regulatory Filing fees and access to potential grant funding.
  • The SUBWAY.com's Stock Focus List highlighted a 1% increase in Human Genome Sciences, Inc. (NASDAQ: HGSI), up 3 million shares, Rambus Inc. (NASDAQ: RMBS), up 2 million shares, and Cognos (NASDAQ: COGN), up 1 million shares.
  • As of Friday, 06-02-2006 23:59, the latest Comtex SmarTrend(SM) Alert indicated a DOWNTREND on 05-11-2006 for COGN @ $36.33, 03-27-2006 for HGSI @ $11.02, and 05-03-2006 for RMBS @ $35.66.

Sources:

  • TheSUBWAY.com, Copyright 2006 Market Wire, All rights reserved.
  • Xechem International Inc. (OTCBB: XKEM), announcement of Orphan Drug designation.
  • Comtex News Network, Inc., Copyright 2006, All rights reserved.

Read more